April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
Association Between Response to Intravitreal Ranibizumab and Known AMD Susceptibility Loci in Age-Related Macular Degeneration
M. Menghini; F. Sutter; W. Berger; J. Fleischhauer; S. Labs; M. Kurz-Levin; B. Kloeckener-Gruissem; S. Michels; D. Barthelmes
Author Affiliations & Notes
  • M. Menghini
    Eye Clinic, University Hospital of Zurich, Zurich, Switzerland
  • F. Sutter
    Eye Clinic, University Hospital of Zurich, Zurich, Switzerland
  • W. Berger
    Institute of Medical Genetics, Division of Medical and Molecular Genetics, University Zurich, Schwerzenbach, Switzerland
  • J. Fleischhauer
    Eye Clinic, University Hospital of Zurich, Zurich, Switzerland
  • S. Labs
    Institute of Medical Genetics, Division of Medical and Molecular Genetics, University Zurich, Schwerzenbach, Switzerland
  • M. Kurz-Levin
    Eye Clinic, University Hospital of Zurich, Zurich, Switzerland
  • B. Kloeckener-Gruissem
    Institute of Medical Genetics, Division of Medical and Molecular Genetics, University Zurich, Schwerzenbach, Switzerland
  • S. Michels
    Eye Clinic, University Hospital of Zurich, Zurich, Switzerland
  • D. Barthelmes
    Save Sight Institute, University of Sydney, Sydney, Australia
  • Footnotes
    Commercial Relationships  M. Menghini, None; F. Sutter, Novartis, C; W. Berger, None; J. Fleischhauer, None; S. Labs, None; M. Kurz-Levin, None; B. Kloeckener-Gruissem, None; S. Michels, None; D. Barthelmes, None.
  • Footnotes
    Support  Novartis
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 1284. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      Association Between Response to Intravitreal Ranibizumab and Known AMD Susceptibility Loci in Age-Related Macular Degeneration
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      M. Menghini, F. Sutter, W. Berger, J. Fleischhauer, S. Labs, M. Kurz-Levin, B. Kloeckener-Gruissem, S. Michels, D. Barthelmes; Association Between Response to Intravitreal Ranibizumab and Known AMD Susceptibility Loci in Age-Related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2010;51(13):1284.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Purpose: : Recent studies revealed different responses to anti VEGF treatment in patients with neovascular AMD, despite similar baseline characteristics and comparable treatment regimens. We evaluated a possible relationship between treatment outcome and the individual’s genetic background.

Methods: : Clinical data of neovascular AMD patients treated with intravitreal Ranibizumab were collected during a period of at least 12 months. Percentiles of the visual acuity were calculated at month 12. Genotypes for five SNPs, which previously had been shown to be involved in AMD, were determined by DNA sequencing or the Taq-man SNP assay. From the assessment of the course of visual acuity two groups were created: 75th percentile (good responders) and 25th percentile (bad responders). Genotypes for SNPs rs1061170 in CFH, rs641153 in CFB, rs11200638 in HTRA1, rs10490924 in LOC387715 and rs1413711 in VEGFA from individuals of these two groups were analyzed.

Results: : We did not find an association between treatment outcome and the allele frequency of the five loci. In contrast, one genotype of CFH was found at a significantly higher frequency in patients that did not respond well to the treatment compared to those that responded well. The difference was statistically significant, yielding an odds ratio of 2.8.

Conclusions: : At this time, a promising trend of association of complement factor H with outcome of treatment supports our hypothesis. Patients with this particular genotype are approximately 3 times less likely to experience a successful treatment. Improved treatment regimens may result from these studies.

Keywords: age-related macular degeneration • genetics • clinical (human) or epidemiologic studies: outcomes/complications 
© 2010, The Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Permission to republish any abstract or part of an abstract in any form must be obtained in writing from the ARVO Office prior to publication.
Copyright © 2015 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept